The participation of caregivers, who play a crucial role in the recovery of patients with gastrointestinal tumors, in family nutrition support decisions can help tailor nutrition plans to meet the specific needs and lifestyle habits of the patient, thereby enhancing the effectiveness of nutritional intake.

To assess the impact of caregiver-shared decision-making in family nutritional support with mindfulness-based behavioral therapy on the risk of malnutrition and mood states in patients with gastrointestinal tumors.

Patients with gastrointestinal tumors (n = 118) treated at the Jiangnan University Affiliated Hospital between December 2021 and March 2024 were assigned to the observation (n = 59) and control (n = 59) groups using the random number table method. In addition to the standard treatment and basic nursing measures implemented in the control group, the integrated approach was implemented in the observation group. The nutritional and mood state indicators, compliance, and satisfaction before and 6 months after implementing the intervention were compared between the groups.

The body mass index, serum albumin levels, and transferrin levels, as well as the scores for all seven dimensions of the Profile of Mood States questionnaire, in the observation were higher than those in the control group after the 6-month follow-up period (P < 0.05). However, the Nutrition Risk Screening 2002 and Mindful Attention Awareness Scale scores were lower than those in the control group (P < 0.05). The compliance and satisfaction rates were 94.92% and 98.31%, respectively, which were higher than those of the control group (79.66% and 88.14%, respectively; P < 0.05).

The implementation of the integrated approach significantly reduced the risk of malnutrition and improved mood states in patients with gastrointestinal tumors. Moreover, the compliance and satisfaction rates were higher.

The aim of this study was to examine the relationship between lean body mass (LBM) and the incidence and severity of neutropenia in patients with malignant tumors from Northern China who have received nanoparticle albumin-bound paclitaxel. Twenty-six patients with pathologically confirmed malignant tumors were prospectively included in this study. These 26 patients were divided into Group A (sarcopenia) and Group B (nonsarcopenia). Group A comprised 50% (13/26) of the patients, while Group B comprised the other 50% (13/26). There was no statistically significant difference between both groups in terms of body surface area (P = .052). The incidence of neutropenia in Group A was 76.9% compared to 61.5% in Group B (P = .0673). The incidence of Grade 3 and severe neutropenia was 76.9% versus 61.5% in Groups A and B, respectively (P = .645). These 26 patients were divided into Groups 1 and 2 based on the administered nab-paclitaxel dose per kilogram of LBM, with both groups receiving a body surface area dose of 260 mg/m2 . Group 1 received a nab-paclitaxel dose of 14.19 mg/kg of LBM, whereas Group 2 received 11.37 mg/kg of LBM. In Group 1, the incidence of neutropenia was 71.4%, whereas it was 66.7% in Group 2. Grade 3 or higher neutropenia incidence was 28.6% in Group 1 versus 16.7% in Group 2. Patients with sarcopenia in northern China experienced a higher incidence of severe neutropenia after receiving nab-paclitaxel than patients without sarcopenia. Higher drug dose intensity per unit of LBM may be a contributing factor.